Johnson & Johnson (JNJ) is down on a 30-day chart but not on a one-year, says Patrick Ciummo of Charles Schwab. He notes the stock's weakness and overhead resistance in the short-term, and as he points out, investors will want to mind the 20-day SMA for the healthcare giant.